Related Experiment Video
Updated: Nov 5, 2025
Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Association of Circulating ICAM3 Concentrations with Severity and Short-term Outcomes of Acute Ischemic Stroke
Hu Zicheng1, Yang Xiao2, Huang Rongzhong3
1Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Abstract:
Increased circulating intercellular adhesion molecule 3 (ICAM3) is associated with a risk of acute ischemic stroke. This study aims to investigate the association of serum levels of ICAM3 with the severity and short-term outcomes of ischemic stroke. This study recruited 152 stroke patients with supratentorial cerebral infarcts and 133 healthy controls. Patients were followed up for 2 weeks since admission for observation of functional outcomes. Serum ICAM3 concentrations at baseline were determined by Elisa. Serum ICAM3 concentrations were higher in stroke patients than in healthy controls. Serum concentrations of ICAM3 were not associated with stroke severity at baseline, as reflected by NIH Stroke Scale (NIHSS) and infarction volume. However, serum ICAM3 levels were positively associated with mRS scores at 2 weeks since admission. Furthermore, regression analyses found that increased serum ICAM3 levels were associated with worse short-term functional outcomes of stroke. These findings imply that circulating ICAM3 might be a potential short-term prognostic biomarker for acute ischemic stroke.
Insights
Elevated intercellular adhesion molecule 3 (ICAM3) in the blood is linked to poorer outcomes in acute ischemic stroke patients. Higher ICAM3 levels correlate with worse functional recovery within two weeks post-stroke.
Area of Science:
- Neurology
- Immunology
- Biomarker Research
Background:
- Increased circulating intercellular adhesion molecule 3 (ICAM3) is recognized as a risk factor for acute ischemic stroke.
- Understanding the role of ICAM3 in stroke severity and prognosis is crucial for patient management.
Purpose of the Study:
- To investigate the association between serum ICAM3 levels and the severity of acute ischemic stroke.
- To evaluate the relationship between serum ICAM3 levels and short-term functional outcomes in stroke patients.
Main Methods:
- Serum ICAM3 concentrations were measured using ELISA in 152 acute ischemic stroke patients and 133 healthy controls.
- Stroke severity was assessed using the NIH Stroke Scale (NIHSS) and infarction volume.
- Functional outcomes were evaluated using modified Rankin Scale (mRS) scores at 2-week follow-up.
Main Results:
- Stroke patients exhibited significantly higher serum ICAM3 levels compared to healthy controls.
- Serum ICAM3 concentrations did not correlate with baseline stroke severity (NIHSS, infarction volume).
- Elevated serum ICAM3 levels were positively associated with higher mRS scores at 2 weeks, indicating worse functional outcomes.
Conclusions:
- Circulating ICAM3 levels are elevated in acute ischemic stroke patients.
- Serum ICAM3 is not associated with stroke severity but predicts worse short-term functional outcomes.
- ICAM3 may serve as a valuable short-term prognostic biomarker for acute ischemic stroke.
